Corey Majors
Endocrinology, Diabetes & Metabolism · Hammond, LANPI 1134495526
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Lilly USA, LLC at 59.0% of the total. 2025 is the largest year on record at $27,638, 3.7 times the $7,400 reported in 2019.
Across 598 payments — averaging $74.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$26K
- Novo Nordisk$5K
- Sanofi-aventis U.S. LLC$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AstraZeneca$2K
- Medtronic$1K
- plus $5K from 36 others
What the payments were for
- Consulting fees$5,82413%
- Speaking & faculty fees$24,77955%
- Travel & lodging$3,4728%
- Food & beverage$10,56324%
- Education$1160%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,813 in reported general payments places this provider in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 897 | $1,060,951 |
| OzempicSemaglutide | 742 | $822,146 |
| JardianceEmpagliflozin | 706 | $619,966 |
| TrulicityDulaglutide | 490 | $526,709 |
| JanuviaSitagliptin Phosphate | 235 | $210,392 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 124 | $103,353 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 572 | $72,973 |
| Tresiba Flextouch U-100Insulin Degludec | 113 | $70,700 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $62,667 |
| FarxigaDapagliflozin Propanediol | 61 | $61,760 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 59 | $50,028 |
| Novolog FlexpenInsulin Aspart | 207 | $45,052 |
| Humalog Kwikpen U-100Insulin Lispro | 191 | $34,613 |
| TymlosAbaloparatide | 13 | $33,896 |
| KerendiaFinerenone | 47 | $31,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $26,428 | $1,591,8621,411 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Levemir | $5,330 | $868,502815 claims |
| Boehringer IngelheimJardiance, Tradjenta | $278 | $649,157758 claims |
| MerckJanuvia, Janumet, Janumet Xr | $276 | $228,225264 claims |
| AstraZenecaFarxiga | $1,758 | $61,76061 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $3,545 | $55,30595 claims |
| Radius Health, Inc.Tymlos | $160 | $33,89613 claims |
| BayerKerendia | $260 | $31,92947 claims |
| AbbVieSynthroid, Armour Thyroid | $269 | $14,091184 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $33 | $7,032853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Hammond
- Abdul KhanHammond$587K
- Harold MillerHammond$73K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.